JP2020508691A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508691A5 JP2020508691A5 JP2019548419A JP2019548419A JP2020508691A5 JP 2020508691 A5 JP2020508691 A5 JP 2020508691A5 JP 2019548419 A JP2019548419 A JP 2019548419A JP 2019548419 A JP2019548419 A JP 2019548419A JP 2020508691 A5 JP2020508691 A5 JP 2020508691A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- soluble
- fusion protein
- protein complex
- 15rαsu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims description 75
- 102000037865 fusion proteins Human genes 0.000 claims description 75
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 102000004169 proteins and genes Human genes 0.000 claims description 70
- 108090000172 Interleukin-15 Proteins 0.000 claims description 44
- 102000003812 Interleukin-15 Human genes 0.000 claims description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 108060003951 Immunoglobulin Proteins 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 14
- 102000018358 immunoglobulin Human genes 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims description 7
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000000710 homodimer Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 230000007928 solubilization Effects 0.000 claims 1
- 238000005063 solubilization Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 45
- 238000000034 method Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 18
- 210000002865 immune cell Anatomy 0.000 description 17
- 108040003610 interleukin-12 receptor activity proteins Proteins 0.000 description 8
- 108040002014 interleukin-18 receptor activity proteins Proteins 0.000 description 8
- 102000008625 interleukin-18 receptor activity proteins Human genes 0.000 description 8
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 7
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 102220311640 rs1382779104 Human genes 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108010053727 Interleukin-15 Receptor alpha Subunit Proteins 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000006918 subunit interaction Effects 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000012526 B-cell neoplasm Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 201000006974 gastroesophageal cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022194613A JP2023027174A (ja) | 2017-03-06 | 2022-12-06 | Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合 |
| JP2024082540A JP7720950B2 (ja) | 2017-03-06 | 2024-05-21 | Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762467623P | 2017-03-06 | 2017-03-06 | |
| US62/467,623 | 2017-03-06 | ||
| PCT/US2018/021220 WO2018165208A1 (en) | 2017-03-06 | 2018-03-06 | Il-15-based fusions to il-12 and il-18 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022194613A Division JP2023027174A (ja) | 2017-03-06 | 2022-12-06 | Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508691A JP2020508691A (ja) | 2020-03-26 |
| JP2020508691A5 true JP2020508691A5 (enExample) | 2021-04-15 |
| JP7191030B2 JP7191030B2 (ja) | 2022-12-16 |
Family
ID=63448011
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548419A Active JP7191030B2 (ja) | 2017-03-06 | 2018-03-06 | Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合 |
| JP2022194613A Pending JP2023027174A (ja) | 2017-03-06 | 2022-12-06 | Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合 |
| JP2024082540A Active JP7720950B2 (ja) | 2017-03-06 | 2024-05-21 | Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022194613A Pending JP2023027174A (ja) | 2017-03-06 | 2022-12-06 | Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合 |
| JP2024082540A Active JP7720950B2 (ja) | 2017-03-06 | 2024-05-21 | Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合 |
Country Status (8)
| Country | Link |
|---|---|
| US (8) | US11129883B2 (enExample) |
| EP (1) | EP3592778A4 (enExample) |
| JP (3) | JP7191030B2 (enExample) |
| KR (4) | KR102739572B1 (enExample) |
| CN (2) | CN117986384A (enExample) |
| AU (1) | AU2018231170B2 (enExample) |
| CA (2) | CA3055318C (enExample) |
| WO (1) | WO2018165208A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2690825C (en) * | 2007-05-11 | 2019-02-12 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
| CA3055318C (en) | 2017-03-06 | 2025-11-25 | Altor Bioscience Corp | Il-15-based fusions to il-12 and il-18 |
| CN107384859A (zh) * | 2017-09-05 | 2017-11-24 | 四川新生命干细胞科技股份有限公司 | 一种高纯度nk细胞的分离培养方法 |
| WO2019051015A1 (en) | 2017-09-06 | 2019-03-14 | Yale University | VARIANTS OF INTERLEUKIN-18 AND METHODS OF USE |
| WO2019166658A1 (en) * | 2018-03-01 | 2019-09-06 | Fundación Para La Investigación Biomédica Del Hospital Gregorio Marañón | Method for obtaining regulatory t cells derived from thymic tissue and use of said cells as cell immunotherapy in immune system disorders |
| WO2020023713A1 (en) * | 2018-07-26 | 2020-01-30 | Nantbio, Inc. | Tri-cytokine txm compositions and methods |
| NZ772550A (en) | 2018-08-30 | 2025-08-29 | Immunitybio Inc | Multi-chain chimeric polypeptides and uses thereof |
| CN112888445B (zh) | 2018-08-30 | 2025-06-10 | 免疫生物公司 | 治疗老年化相关病症的方法 |
| CN120535649A (zh) | 2018-08-30 | 2025-08-26 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| CN118976120A (zh) * | 2018-09-07 | 2024-11-19 | 南特生物公司 | 刺激hank和nk92mi细胞的靶向il-12治疗和方法 |
| KR20220035394A (ko) * | 2019-06-21 | 2022-03-22 | 에이치씨더블유 바이올로직스, 인크. | 다중-사슬 키메라 폴리펩티드 및 이의 용도 |
| US20210008107A1 (en) * | 2019-07-08 | 2021-01-14 | Nantkwest, Inc. | CIML NK cells and Methods Therefor |
| US11453862B2 (en) | 2019-07-08 | 2022-09-27 | Immunitybio, Inc. | Mononuclear cell derived NK cells |
| CN113166726A (zh) | 2019-07-08 | 2021-07-23 | 南克维斯特公司 | 单核细胞源性nk细胞 |
| CN113195706A (zh) * | 2019-07-08 | 2021-07-30 | 南克维斯特公司 | Ciml nk细胞及其方法 |
| WO2021044439A1 (en) * | 2019-09-08 | 2021-03-11 | Immunoadaptive Cell Therapy Pvt Ltd. | Inducible cytokine signals & methods for immunotherapy |
| RU2753282C2 (ru) * | 2019-09-19 | 2021-08-12 | Закрытое Акционерное Общество "Биокад" | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
| CA3157024A1 (en) * | 2019-10-03 | 2021-04-08 | Xencor, Inc. | Targeted il-12 heterodimeric fc-fusion proteins |
| WO2021097227A1 (en) * | 2019-11-14 | 2021-05-20 | Altor Bioscience, Llc | Il-15 fusion protein enhanced adoptive cell therapeutics |
| KR102400884B1 (ko) * | 2019-11-15 | 2022-05-23 | 주식회사 제넥신 | 변형된 인터루킨-7 및 인터루킨-2를 포함하는 융합단백질 및 이의 용도 |
| AU2021220870A1 (en) | 2020-02-11 | 2022-08-04 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| WO2021163298A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| KR20230137392A (ko) * | 2021-03-03 | 2023-10-04 | 이뮤니티바이오, 인크. | 고도로 강력한 m-cenk 세포 및 방법 |
| EP4351320A1 (en) | 2021-06-09 | 2024-04-17 | ImmunityBio, Inc. | Methods and systems for producing a protein of interest in a plant |
| CN114853899B (zh) * | 2021-11-02 | 2024-05-28 | 北京华奥玄德生物医药科技有限公司 | 一种il-12和il-18变体的融合蛋白及其制备方法和用途 |
| WO2024040132A2 (en) * | 2022-08-16 | 2024-02-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Synergistic interactions for improved cancer treatment |
| KR20250167051A (ko) * | 2023-03-31 | 2025-11-28 | 이뮤니티바이오, 인크. | Il-12/il-18 슈퍼카인 |
| WO2024259391A2 (en) * | 2023-06-14 | 2024-12-19 | Fuse Biotherapeutics Inc. | Single-and multi-cytokine fusion proteins and uses thereof |
| WO2025068413A1 (en) * | 2023-09-28 | 2025-04-03 | Prokarium Limited | Interleukin 18 variants |
| WO2025184052A1 (en) * | 2024-02-26 | 2025-09-04 | Allegheny Singer Research Institute | Interleukin 2 and interleukin 12 fusion proteins and methods of using |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| WO1994004689A1 (en) | 1992-08-14 | 1994-03-03 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant toxin with increased half-life |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5534592A (en) | 1995-09-22 | 1996-07-09 | The Goodyear Tire & Rubber Company | High performance blend for tire treads |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| DE60336930D1 (de) | 2002-12-31 | 2011-06-09 | Schering Corp | IL-27 et IL-2 pour le traitement du cancer |
| DE602004031341D1 (de) | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| US8772451B2 (en) | 2003-11-10 | 2014-07-08 | Altor Bioscience Corporation | Soluble TCR molecules and methods of use |
| CA2690825C (en) * | 2007-05-11 | 2019-02-12 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
| EP3176264B1 (en) | 2007-05-30 | 2018-09-26 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
| US9931386B2 (en) * | 2008-06-16 | 2018-04-03 | Atsuo Ochi | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity |
| CN105017429B (zh) * | 2010-09-21 | 2021-04-06 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
| CA3101783C (en) * | 2011-10-11 | 2023-01-31 | Universitat Zurich Prorektorat Mnw | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
| EP3160498B1 (en) | 2014-06-30 | 2021-10-06 | Altor BioScience Corporation | Il-15-based molecules and methods of use thereof |
| WO2018075989A1 (en) * | 2016-10-21 | 2018-04-26 | Altor Bioscience Corporation | Multimeric il-15-based molecules |
| CA3055318C (en) | 2017-03-06 | 2025-11-25 | Altor Bioscience Corp | Il-15-based fusions to il-12 and il-18 |
| US20190048055A1 (en) | 2017-03-31 | 2019-02-14 | Altor Bioscience Corporation | Alt-803 in combination with anti-cd38 antibody for cancer therapies |
| CA3074635A1 (en) | 2017-08-28 | 2019-03-07 | Altor Bioscience Llc | Il-15-based fusions to il-7 and il-21 |
| TW202003011A (zh) | 2018-03-26 | 2020-01-16 | 美商艾爾特生物科技責任有限公司 | 抗ＰＤＬ１、ＩＬ－１５及ＴＧＦ－β受體組合分子 |
-
2018
- 2018-03-06 CA CA3055318A patent/CA3055318C/en active Active
- 2018-03-06 CN CN202311813891.8A patent/CN117986384A/zh active Pending
- 2018-03-06 KR KR1020237042270A patent/KR102739572B1/ko active Active
- 2018-03-06 KR KR1020257032318A patent/KR20250150164A/ko active Pending
- 2018-03-06 KR KR1020247039400A patent/KR102867975B1/ko active Active
- 2018-03-06 EP EP18764359.8A patent/EP3592778A4/en active Pending
- 2018-03-06 KR KR1020197029313A patent/KR102625293B1/ko active Active
- 2018-03-06 JP JP2019548419A patent/JP7191030B2/ja active Active
- 2018-03-06 CA CA3216726A patent/CA3216726C/en active Active
- 2018-03-06 CN CN201880016721.8A patent/CN110785435B/zh active Active
- 2018-03-06 AU AU2018231170A patent/AU2018231170B2/en active Active
- 2018-03-06 US US15/913,837 patent/US11129883B2/en active Active
- 2018-03-06 WO PCT/US2018/021220 patent/WO2018165208A1/en not_active Ceased
-
2021
- 2021-09-27 US US17/486,683 patent/US11571470B2/en active Active
-
2022
- 2022-08-19 US US17/820,980 patent/US11612645B2/en active Active
- 2022-12-06 JP JP2022194613A patent/JP2023027174A/ja active Pending
-
2023
- 2023-02-13 US US18/168,428 patent/US11872272B2/en active Active
- 2023-12-01 US US18/526,598 patent/US11975059B2/en active Active
-
2024
- 2024-03-20 US US18/611,464 patent/US20240252609A1/en not_active Abandoned
- 2024-05-21 JP JP2024082540A patent/JP7720950B2/ja active Active
- 2024-09-25 US US18/896,286 patent/US12233116B2/en active Active
-
2025
- 2025-01-15 US US19/021,639 patent/US20250152686A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508691A5 (enExample) | ||
| CN112534052B (zh) | 全新il-21前药及使用方法 | |
| TWI669311B (zh) | Ｉｌ－１５異源二聚體蛋白及其用途 | |
| CN112654636A (zh) | 可活化白介素12多肽及其使用方法 | |
| JP7121496B2 (ja) | 癌治療で使用するためのペグ化インターロイキン－１０ | |
| JP2021502810A5 (enExample) | ||
| JP7423607B2 (ja) | インターロイキン ２突然変異タンパク質およびｉ型インターフェロンで構成される融合タンパク質 | |
| JP2003507012A5 (enExample) | ||
| JP7356726B2 (ja) | タンパク性ヘテロ二量体及びその使用 | |
| EA012622B1 (ru) | Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки | |
| CN102906112A (zh) | Trail r2-特异性多聚体支架 | |
| EA011992B1 (ru) | Гибридный белок антитела l19 к фибронектину ed-b и интерлейкина 12 | |
| EP4284819A1 (en) | Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide | |
| EP4019536A1 (en) | Immunocytokine, preparation for same, and uses thereof | |
| JP2004508828A (ja) | 標的−特異的プロドラッグとしての使用のための抗体サイトカイン−サイトカインインヒビター（セレクトカイン）からの融合タンパク質 | |
| JP2008535475A5 (enExample) | ||
| US20230201364A1 (en) | Antibody conjugates and manufacture thereof | |
| JPWO2021189139A5 (enExample) | ||
| TW201841944A (zh) | 4-1bbl變異體及包含其之融合蛋白 | |
| WO2019096026A1 (zh) | 抗il-17抗体/tnfr ecd融合蛋白及其用途 | |
| JP2008521426A5 (enExample) | ||
| CN116134139A (zh) | 一种转基因免疫效应细胞及其应用 | |
| JP2014124186A (ja) | 多価抗体フラグメントおよびその三量体化複合体 | |
| CA3180251A1 (en) | Cytokine conjugates | |
| WO2023143308A1 (zh) | 一种pd1抗体与白介素2融合的双功能分子 |